Urine Cytology and Adjunct Markers for Detection and Surveillance of Bladder Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2010 Aug 25

PMID 20733951

Citations 46

Authors

Peggy S Sullivan

Jessica B Chan

Mary R Levin

Jianyu Rao

Affiliations

Soon will be listed here.

Abstract

Urine cytology coupled with cystoscopic examination has been and remains the standard in the initial evaluation of lower urinary tract lesions to rule out bladder cancer. However, cystoscopy is invasive and may miss some flat lesions, whereas cytology has low sensitivity in low-grade papillary disease. Additional lab-based or office-based markers are needed to aid in the evaluation of these lesions. Recently, many such markers have been developed for the purpose of improving the cytologic diagnosis of bladder malignancies. In this review, we will first discuss conventional cytomorphologic analysis of urine cytology followed by a discussion of markers that have been developed in the past for detection and surveillance of urothelial carcinoma. We will focus on how these markers can be used in conjunction with urine cytology in daily practice.

Citing Articles

Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).

Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W Int J Oncol. 2025; 66(3).

PMID: 39917986 PMC: 11837902. DOI: 10.3892/ijo.2025.5724.

Urinary DNA Methylation Test for Bladder Cancer Diagnosis.

Jeong I, Yun S, Ha H, Kang S, Lee S, Park S JAMA Oncol. 2025; .

PMID: 39883469 PMC: 11783243. DOI: 10.1001/jamaoncol.2024.6160.

Is prostatic adenocarcinoma detectable by urine cytology-A multicenter retrospective review.

Tang C, Li J, Leung K, Ma H, Ng J, Yan R Prostate. 2024; 85(1):97-104.

PMID: 39400384 PMC: 11609891. DOI: 10.1002/pros.24805.

The Simultaneous Use of Bladder Epicheck and Urinary Cytology Can Improve the Sensitivity and Specificity of Diagnostic Follow-Up of Urothelial Lesions: Up-to-Date Data from a Multi-Institutional Cohort.

Pepe L, Fiorentino V, Pizzimenti C, Riganati G, Franchina M, Micali M Diseases. 2024; 12(9).

PMID: 39329888 PMC: 11431392. DOI: 10.3390/diseases12090219.

Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review.

Coelho K, Wosniaki D, Marin A, Fabris L, Dos Reis R, Aoki M Front Oncol. 2024; 14:1441883.

PMID: 39184050 PMC: 11341357. DOI: 10.3389/fonc.2024.1441883.

References

Eissa S, Swellam M, el-Mosallamy H, Mourad M, Hamdy N, Kamel K . Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res. 2003; 23(5b):4347-55. View

Grossman H, Washington Jr R, Carey T, Liebert M . Alterations in antigen expression in superficial bladder cancer. J Cell Biochem Suppl. 1992; 16I:63-8. DOI: 10.1002/jcb.240501313. View

Witjes J, van der Poel H, van Balken M, Debruyne F, Schalken J . Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol. 1998; 33(4):387-91. DOI: 10.1159/000019621. View

Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G, Piazzini M . Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol. 2006; 175(6):2032-7. DOI: 10.1016/S0022-5347(06)00283-7. View

Mao L, Lee D, Tockman M, Erozan Y, Askin F, Sidransky D . Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A. 1994; 91(21):9871-5. PMC: 44919. DOI: 10.1073/pnas.91.21.9871. View

Soloway M, Briggman V, Carpinito G, Chodak G, Church P, Lamm D . Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996; 156(2 Pt 1):363-7. DOI: 10.1097/00005392-199608000-00008. View

Kavaler E, Landman J, Chang Y, Droller M, Liu B . Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer. 1998; 82(4):708-14. DOI: 10.1002/(sici)1097-0142(19980215)82:4<708::aid-cncr14>3.0.co;2-1. View

Yates D, Rehman I, Meuth M, Cross S, Hamdy F, Catto J . Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene. 2005; 25(13):1984-8. DOI: 10.1038/sj.onc.1209209. View

Topsakal M, Karadeniz T, Anac M, Donmezer S, Besisik A . Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol. 2001; 39(3):287-91. DOI: 10.1159/000052455. View

10.

Retz M, Lehmann J, Amann E, Wullich B, Roder C, Stockle M . Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol. 2002; 169(1):86-9. DOI: 10.1016/S0022-5347(05)64042-6. View

11.

Halling K, King W, Sokolova I, Karnes R, Meyer R, Powell E . A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002; 167(5):2001-6. View

12.

Liu B, Loughlin K . Telomerase in human bladder cancer. Urol Clin North Am. 2000; 27(1):115-23, x. DOI: 10.1016/s0094-0143(05)70239-1. View

13.

Soyuer I, Sofikerim M, Tokat F, Soyuer S, Ozturk F . Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression. Diagn Pathol. 2009; 4:20. PMC: 2709650. DOI: 10.1186/1746-1596-4-20. View

14.

Mora L, Nicosia S, Pow-Sang J, Ku N, Diaz J, Lockhart J . Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. J Urol. 1996; 156(1):49-54; discussion 54-5. DOI: 10.1016/s0022-5347(01)65934-2. View

15.

Boman H, Hedelin H, Jacobsson S, Holmang S . Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol. 2002; 168(5):1955-9. DOI: 10.1016/S0022-5347(05)64271-1. View

16.

Melissourgos N, Kastrinakis N, Skolarikos A, Pappa M, Vassilakis G, Gorgoulis V . Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology. 2005; 66(3):536-41. DOI: 10.1016/j.urology.2005.04.022. View

17.

Golijanin D, Shapiro A, Pode D . Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. J Urol. 2000; 164(6):1922-5. View

18.

Mourah S, Cussenot O, Vimont V, Desgrandchamps F, Teillac P, Le Duc A . Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer. 1998; 79(6):629-33. DOI: 10.1002/(sici)1097-0215(19981218)79:6<629::aid-ijc13>3.0.co;2-1. View

19.

Sarosdy M, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L . Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002; 168(5):1950-4. DOI: 10.1016/S0022-5347(05)64270-X. View

20.

Lotan Y, Roehrborn C . Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003; 61(1):109-18; discussion 118. DOI: 10.1016/s0090-4295(02)02136-2. View